Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized depression drug shows promise in Mid-Stage trial

NCT ID NCT05712187

Completed Disease control Sponsor: Alto Neuroscience Source: ClinicalTrials.gov ↗

Summary

This study tested whether ALTO-100, a new investigational medication, helps reduce symptoms of major depression. It involved 301 adults with moderate to severe depression, who took the drug either by itself or added to their current antidepressant for 6 weeks. Researchers measured changes in depression symptoms to see if certain patient characteristics made people more likely to respond to the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site 108

    Jackson, Mississippi, 39216, United States

  • Site 116

    Sacramento, California, 95655, United States

  • Site 118

    Fresno, California, 93703, United States

  • Site 120

    Houston, Texas, 77054, United States

  • Site 121

    Draper, Utah, 84020, United States

  • Site 136

    Chandler, Arizona, 85226, United States

  • Site 137

    Carmel, Indiana, 46032, United States

  • Site 139

    Little Rock, Arkansas, 72211, United States

  • Site 141

    Costa Mesa, California, 92626, United States

  • Site 142

    Lincoln, Nebraska, 68562, United States

  • Site 144

    Las Vegas, Nevada, 89102, United States

  • Site 147

    Fort Worth, Texas, 76104, United States

  • Site 151

    Baltimore, Maryland, 21229, United States

  • Site 157

    North Charleston, South Carolina, 29405, United States

  • Site 171

    Jackson, Mississippi, 39216, United States

  • Site 172

    Houston, Texas, 77081, United States

  • Site 173

    Huntsville, Alabama, 35801, United States

  • Site 174

    Birmingham, Alabama, 35294, United States

  • Site 175

    Westlake, Ohio, 44145, United States

  • Site 178

    Albuquerque, New Mexico, 87109, United States

  • Site 179

    Rancho Cucamonga, California, 91730, United States

  • Site 180

    New York, New York, 10022, United States

  • Site 181

    Imperial, California, 92251, United States

  • Site 182

    Oceanside, California, 92056, United States

  • Site 183

    Memphis, Tennessee, 38119, United States

  • Site 184

    Brooklyn, New York, 11229, United States

  • Site 185

    Centennial, Colorado, 80112, United States

  • Site 186

    Brooksville, Florida, 34613, United States

  • Site 188

    Oceanside, California, 92056, United States

  • Site 204

    Jacksonville, Florida, 32256, United States

  • Site 205

    Orlando, Florida, 32801, United States

  • Site 210

    New York, New York, 10128, United States

  • Site 212

    Tampa, Florida, 33629, United States

  • Site 213

    Tampa, Florida, 33629, United States

Conditions

Explore the condition pages connected to this study.

MAJOR DEPRESSIVE DISORDER